First-in-human phase I studies of YJ001 spray applied to local skin in healthy subjects and patients with diabetic neuropathic pain

References

• International diabetes federation (idf). Idf diabetes atlas 10th edition . 2021. Accessed 2 November 2022 . https://diabetesatlas.org/atlas/tenth-edition/
   Google Scholar
• Sun H, Saeedi P, Karuranga S, et al. Idf diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188.
   PubMed Web of Science ®Google Scholar
• Li X, Shi S, Jing D, et al. Signal transduction mechanism of exosomes in diabetic complications (review). Exp Ther Med. 2022;23(2):155. DOI:10.3892/etm.2021.11078
   PubMed Web of Science ®Google Scholar
• Rosenberger DC, Blechschmidt V, Timmerman H, et al. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm. ViennaAustria : 1996. 2020;127(4):589–624. DOI:10.1007/s00702-020-02145-7.
   PubMed Web of Science ®Google Scholar
• Schreiber AK, Nones CF, Reis RC, et al. Diabetic neuropathic pain: physiopathology and treatment. WJD. 2015;6(3):432–444. DOI:10.4239/wjd.v6.i3.432
   Google Scholar
• Spallone V, Lacerenza M, Rossi A, et al. Painful diabetic polyneuropathy: approach to diagnosis and management. Clin J Pain. 2012;28(8):726–743. DOI:10.1097/AJP.0b013e318243075c
   PubMed Web of Science ®Google Scholar
• Stanos SP, Galluzzi KE. Topical therapies in the management of chronic pain. Postgrad Med. 2013;125(4 Suppl 1):25–33.
   PubMedGoogle Scholar
• Argoff CE. Topical analgesics in the management of acute and chronic pain. Mayo Clin Proc. 2013;88(2):195–205.
   PubMed Web of Science ®Google Scholar
• Arnstein PM. The future of topical analgesics. Postgrad Med. 2013;125(4 Suppl 1):34–41.
   PubMedGoogle Scholar
• Barkin RL. The pharmacology of topical analgesics. Postgrad Med. 2013;125(4 Suppl 1):7–18.
   PubMedGoogle Scholar
• Yang XD, Fang PF, Xiang DX, et al. Topical treatments for diabetic neuropathic pain. Exp Ther Med. 2019;17(3):1963–1976. DOI:10.3892/etm.2019.7173
   PubMed Web of Science ®Google Scholar
• Aslam A, Singh J, Rajbhandari S. Pathogenesis of painful diabetic neuropathy. Pain research and treatment. Pain Res Treat. 2014;2014:1–7.
   Google Scholar
• Bachewal P, Gundu C, Yerra VG, et al. Morin exerts neuroprotection via attenuation of ros induced oxidative damage and neuroinflammation in experimental diabetic neuropathy. Biofactors. 2018;44(2):109–122. DOI:10.1002/biof.1397
   PubMed Web of Science ®Google Scholar
• Dworkin RH. An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clin J Pain. 2002;18(6):343–349.
   PubMed Web of Science ®Google Scholar
• Djouhri L, Fang X, Koutsikou S, et al. Partial nerve injury induces electrophysiological changes in conducting (uninjured) nociceptive and nonnociceptive drg neurons: possible relationships to aspects of peripheral neuropathic pain and paresthesias. Pain. 2012;153(9):1824–1836. DOI:10.1016/j.pain.2012.04.019
   PubMed Web of Science ®Google Scholar
• Zhang J. Stable pharmaceutical composition containing non-steroidal anti-inflammatory drug derivative. US20200360335. 2020. Accessed 2 November 2022 .
   Google Scholar
• Bowman JP, Berger RS, Mills OH, et al. The 21-day human cumulative irritation test can be reduced to 14 days without loss of sensitivity. J Cosmet Sci. 2003;54(5):443–449.
   PubMedGoogle Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: immpact recommendations. Pain. 2005;113(1–2):9–19. DOI:10.1016/j.pain.2004.09.012
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage rct study. Curr Med Res Opin. 2009;25(7):1663–1676. DOI:10.1185/03007990903047880
   PubMed Web of Science ®Google Scholar
• Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61(6):914–918. DOI:10.1001/archneur.61.6.914
   PubMedGoogle Scholar
• Melzack R. The short-form McGill pain questionnaire. Pain. 1987;30(2):191–197.
   PubMed Web of Science ®Google Scholar
• Sloan G, Alam U, Selvarajah D, et al. The treatment of painful diabetic neuropathy. CDR. 2022;18(5):42–96. DOI:10.2174/1573399817666210707112413
   Google Scholar
• Mick G, Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster–a review. Curr Med Res Opin. 2012;28(6):937–951.
   PubMed Web of Science ®Google Scholar
• White WT, Patel N, Drass M, et al. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med. 2003;4(4):321–330. DOI:10.1111/j.1526-4637.2003.03045.x
   PubMed Web of Science ®Google Scholar
• Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale. Curr Med Res Opin. 2004;20 Suppl 2(sup2):S21–8. DOI:10.1185/030079904X12960
   PubMedGoogle Scholar
• Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 2009;29(4):231–241. DOI:10.2165/00044011-200929040-00002
   PubMed Web of Science ®Google Scholar
• Ostrovsky DA. Single treatment with capsaicin 8% patch may reduce pain and sleep interference up to 12 weeks in patients with painful diabetic peripheral neuropathy. Explore (New York, NY). 2017;13(5):351–353.
   PubMedGoogle Scholar
• Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42–53. DOI:10.1016/j.jpain.2016.09.008
   PubMed Web of Science ®Google Scholar
• Lynch ME, Clark AJ, Sawynok J, et al. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005;103(1):140–146. DOI:10.1097/00000542-200507000-00021
   PubMed Web of Science ®Google Scholar
• Ho KY, Huh BK, White WD, et al. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain. 2008;24(1):51–55. DOI:10.1097/AJP.0b013e318156db26
   PubMed Web of Science ®Google Scholar
• Motilal S, Maharaj RG. Nutmeg extracts for painful diabetic neuropathy: a randomized, double-blind, controlled study. J Altern Complement Med. 2013;19(4):347–352.
   PubMed Web of Science ®Google Scholar
• Mahoney JM, Vardaxis V, Moore JL, et al. Topical ketamine cream in the treatment of painful diabetic neuropathy: a randomized, placebo-controlled, double-blind initial study. J Am Podiatr Med Assoc. 2012;102(3):178–183.
   PubMed Web of Science ®Google Scholar
• Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153(9):1815–1823. DOI:10.1016/j.pain.2012.04.014
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. DOI:10.1016/S1474-4422(14)70251-0
   PubMed Web of Science ®Google Scholar
• Agrawal RP, Jain S, Goyal S, et al. A clinical trial of nitrosense patch for the treatment of patients with painful diabetic neuropathy. J Assoc Physicians India. 2014;62(5):385–390.
   PubMedGoogle Scholar